XML 44 R29.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders’ Equity (Tables)
 3 Months Ended
Apr. 04, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocated Stock-Based Compensation
We allocated the stock-based compensation for our 2017 Plan and our 2000 Employee Stock Purchase Plan (as amended and restated, the Amended ESPP) as follows (in thousands):
Three Months Ended March 31,
20252024
Research and development$9,522 $3,892 
Selling, general and administrative16,408 15,221 
Total stock-based compensation
$25,930 $19,113 
Stock-based compensation for each type of award under our 2017 Plan and Amended ESPP were as follows (in thousands):
Three Months Ended March 31,
20252024
Stock options$1,060 $1,738 
Restricted stock units23,102 15,434 
Performance stock units241 727 
Employee stock purchase plan
1,527 1,214 
Total stock-based compensation
$25,930 $19,113 
Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions
We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $47.58 per share for the 2025 TSR-based RSUs and $25.10 per share for the 2025 stock price target-based RSUs:
2025 TSR-based RSUs2025 stock price target-based RSUs
Fair value of Exelixis common stock on grant date
$37.53 $36.92 
Expected volatility
32.63 %38.31 %
Risk-free interest rate
4.0 %3.92 %
Dividend yield
— %— %